On 11 June 2025, Sweden-based Xbrane Biopharma and OneSource Specialty Pharma, an Indian-based CDMO, announced that they have entered a partnership for the commercial manufacture of Xbrane’s biosimilar portfolio.
Xbrane’s biosimilars include Ximluci®, biosimilar to Genentech’s Lucentis® (ranibizumab), which was launched by Xbrane and STADA in Europe in April 2023. On 21 April 2024, the FDA issued a Complete Letter Response regarding Xbrane’s ranibizumab BLA. Xbrane resubmitted its BLA to the FDA in December 2024.
The manufacturing partnership between Xbrane and OneSource closely follows completion of Alvotech’s acquisition of Xbrane’s Swedish R&D operations, as well as XB003, biosimilar to UCB’s Cimzia® (certolizumab pegol), in a deal worth US$28.9m.